Brief: Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation For Coya 302 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)
12/05/2026 13:56
May 12 (Reuters) - Coya Therapeutics Inc COYA.O: COYA THERAPEUTICS HAS BEEN GRANTED U.S. FDA FAST TRACK DESIGNATION FOR COYA 302 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) COYA THERAPEUTICS INC - CONDUCTING PHASE 2 ALSTARS TRIAL OF COYA 302 FOR ALS Source text: ID:nBw2PY0mYa Further company coverage: COYA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Coya Therapeutics
See all newsCoya Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Coya Therapeutics Q2 net loss widens as R&D costs rise
Coya Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Coya Therapeutics Entered Into Sales Agreement, May Offer And Sell From Time To Time Shares Of Co's Common Stock For Up To $30 Million
Brief: Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation For Coya 302 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)